Autophagy and mTOR Signaling: ULK1 Initiation, LC3 Lipidation, Selective Cargo Recognition, and Research Tools

# Autophagy and mTOR Signaling: ULK1 Initiation, LC3 Lipidation, Selective Cargo Recognition, and Research Tools

For Research Use Only (RUO). Not intended for diagnostic, therapeutic, or clinical applications.

---

Introduction: Autophagy as Cellular Quality Control

Macroautophagy (hereafter autophagy) is a highly conserved catabolic process in which cytoplasmic contents — misfolded proteins, dysfunctional organelles, intracellular pathogens, and protein aggregates — are sequestered within double-membrane vesicles (autophagosomes) that subsequently fuse with lysosomes for degradation and nutrient recycling. First described ultrastructurally by de Duve and colleagues in the 1960s, autophagy was catapulted to molecular understanding by Yoshinori Ohsumi's identification of autophagy-related (ATG) genes in yeast (Nobel Prize, 2016), most of which have direct mammalian orthologs.

Autophagy serves multiple cellular functions: (1) nutrient recycling during starvation; (2) protein quality control (clearance of misfolded aggregates); (3) organelle homeostasis (mitophagy, ER-phagy, ribophagy); (4) innate immune defense (xenophagy); and (5) cell death in specific contexts. Dysregulation of autophagy is implicated in cancer (tumor-suppressive and tumor-promoting roles depending on context), neurodegeneration (Parkinson's, Alzheimer's, Huntington's), infectious disease, and aging.

This article provides mechanistic analysis of autophagy initiation through the ULK1 complex, phagophore nucleation via the VPS34/Beclin-1 PI3K complex, autophagosome elongation and LC3 lipidation, selective autophagy through cargo receptor pathways, and the central regulatory role of mTORC1 and AMPK in autophagy control.

---

mTORC1: The Master Autophagy Suppressor

Mechanistic target of rapamycin complex 1 (mTORC1) functions as the primary nutrient/energy sensor that suppresses autophagy under anabolic conditions. Its core components are mTOR (the catalytic kinase), RAPTOR (regulatory-associated protein of mTOR), mLST8/GβL, PRAS40, and DEPTOR.

mTORC1 Activation at the Lysosomal Surface

mTORC1 is activated on the cytoplasmic face of lysosomes through a multi-step process:

Step 1 — Amino acid sensing: Amino acids (particularly leucine, arginine, glutamine) are sensed by multiple lysosomal and cytoplasmic sensors:

• •Ragulator-RAG GTPase complex: The pentameric Ragulator (LAMTOR1-5) anchors RAGA/RAGB and RAGC/RAGD heterodimers to the lysosomal surface. Amino acid sufficiency activates FLCN-FNIP (as a GAP for RAGC/D) → RAGC/D·GDP → active RaG heterodimer (RAGA/B·GTP + RAGC/D·GDP) that directly recruits RAPTOR → mTORC1 recruitment to the lysosome
• •Cytoplasmic leucine sensor (LARS → Sestrin2): Leucine binds LARS (leucyl-tRNA synthetase), which signals through GATOR2 to inhibit GATOR1 (a GAP for RAGA/B) → maintained RAGA·GTP → mTORC1 activation
• •Arginine sensor (SLC38A9/CASTOR1): Lysosomal SLC38A9 senses luminal arginine; cytoplasmic CASTOR1 senses cytoplasmic arginine by direct binding; both regulate GATOR1/GATOR2 balance
• •TFEB inverse regulation: When mTORC1 is active at the lysosome, it phosphorylates TFEB (S142, S211) → TFEB cytoplasmic sequestration by 14-3-3 → suppressed lysosomal biogenesis and autophagy transcription

Step 2 — Growth factor input (TSC1/2 → Rheb): The TSC1-TSC2 complex is a GAP for the small GTPase RHEB. Growth factor receptor → PI3K/AKT → AKT phosphorylates TSC2 (T1462) → TSC1/2 complex dissociation → RHEB remains GTP-bound → GTP-RHEB directly activates mTOR kinase at the lysosomal surface (mechanism involves conformational change in the mTOR kinase domain activation loop). AMPK opposes this through direct TSC2 phosphorylation (S1387, activating GAP activity) and through RAPTOR phosphorylation (S792, allosteric inhibition of mTORC1).

mTORC1 Substrates Relevant to Autophagy

• •ULK1 (S757): mTORC1 phosphorylates ULK1 S757 (human; S758 in some references), which disrupts AMPK binding to ULK1 and suppresses ULK1 kinase activity → autophagy inhibited
• •ATG13 (S258): mTORC1 phosphorylates ATG13 S258, preventing ATG13 from activating ULK1 → additional inhibitory layer
• •4E-BP1 (T37/T46, S65, T70): mTORC1-phosphorylated 4E-BP1 releases eIF4E → cap-dependent translation → anabolic state
• •S6K1 (T389): Ribosome biogenesis, protein synthesis
• •TFEB (S142/S211): Lysosomal biogenesis suppression

---

ULK1 Complex: Autophagy Initiation

The ULK1 (Unc-51-like autophagy activating kinase 1) complex — comprising ULK1, ATG13, FIP200 (RB1CC1), and ATG101 — is the apical kinase complex that initiates autophagosome formation upon mTORC1 inactivation.

Complex Architecture

• •ULK1: Serine/threonine kinase; N-terminal kinase domain, C-terminal MIT domain (microtubule interacting and trafficking) for ATG13 and FIP200 binding; phosphorylated by AMPK (activation) and mTORC1 (inhibition)
• •ATG13: Scaffold; constitutively associated with ULK1 through MIT-HORMA interactions; enhances ULK1 kinase activity ~10-fold; phosphorylated by mTORC1 (S258, inhibitory)
• •FIP200 (RB1CC1): 200 kDa scaffold; binds ATG13 (EAT domain interaction); provides membrane targeting and complex stability; required for ULK1 protein stability
• •ATG101: Stabilizes ATG13 HORMA domain; prevents ATG13 degradation; its WF-finger motif may recruit downstream ATG proteins

AMPK-ULK1 Axis: Autophagy Activation Under Energy Stress

AMP-activated protein kinase (AMPK) directly phosphorylates ULK1 at multiple activating sites: S317, S555, S777 (human). ULK1 S555 is the primary activating phosphorylation — it creates a docking site for 14-3-3 proteins that stabilize ULK1 in an active conformation. Additionally, AMPK phosphorylates RAPTOR S792, inhibiting mTORC1 → releasing mTORC1-mediated ULK1 S757 suppression — a synergistic double mechanism ensuring autophagy activation during energy stress.

Under nutrient-replete conditions: mTORC1 active → ULK1 S757 phosphorylated → autophagy suppressed.

Under nutrient/energy stress: mTORC1 inhibited + AMPK activated → ULK1 S555 phosphorylated, S757 dephosphorylated → ULK1 active → autophagy induced.

ULK1 Substrates

Active ULK1 initiates autophagy by phosphorylating:

• •Beclin-1 (S14): Activates VPS34 PI3K complex → PI3P generation at phagophore
• •AMBRA1 (S52): Activates AMBRA1-dependent VPS34 recruitment to ER/mitochondria contact sites
• •ATG14L (S29): Activates ATG14L-containing VPS34 complex for PI3P generation
• •VPS34 (T159): Direct VPS34 activation
• •ATG9A: Regulates ATG9A trafficking to phagophore assembly site (PAS)
• •SEC16A, ERES components: ER exit site remodeling for phagophore membrane supply

---

VPS34/Beclin-1 Complex: PI3P Generation and Phagophore Nucleation

The class III PI3K VPS34 generates phosphatidylinositol 3-phosphate (PI3P) at the phagophore — the lipid signal that nucleates autophagosome membrane formation. VPS34 operates in two principal complexes:

Complex I (Autophagy-specific): VPS34 + VPS15/p150 + Beclin-1 + ATG14L (BARKOR)

→ Generates PI3P at the phagophore assembly site (omegasome, ER-associated)

→ Promotes autophagy initiation

Complex II (Endosomal/non-autophagy): VPS34 + VPS15/p150 + Beclin-1 + UVRAG

→ Generates PI3P at endosomes

→ Regulates endosomal sorting, autophagosome maturation, and lysosome fusion

Beclin-1 Regulation

Beclin-1 (ATG6 ortholog) is the central regulatory scaffold:

• •BCL-2/BCL-XL inhibition: BCL-2 and BCL-XL bind the BH3 domain of Beclin-1, sequestering it in an autophagically inactive complex. Nutrient starvation, BH3 mimetics (ABT-737, navitoclax), and competitive BH3-only proteins (BAD, NOXA, PUMA) displace BCL-2 → Beclin-1 liberation → VPS34 activation → autophagy
• •Positive regulators: AMBRA1, HMGB1, UVRAG enhance Beclin-1-VPS34 activity
• •Negative regulators: Rubicon (RUN domain protein) binds UVRAG → inhibits VPS34 complex II and autophagosome maturation; spautin-1 inhibits USP10/USP13 deubiquitinases → promotes Beclin-1 ubiquitination and degradation

PI3P Effectors at the Phagophore

PI3P generated by VPS34 Complex I recruits:

• •DFCP1 (Double FYVE-containing protein 1): PI3P sensor marking the omegasome (ER-derived PI3P-enriched structure); marks the phagophore birth site
• •WIPI proteins (WIPI1-4): WD40 repeat PI3P-binding proteins; WIPI2 directly recruits ATG16L1 to the phagophore → required for LC3 lipidation
• •ATG18 (WIPI2) → ATG2A/2B: Bridges phagophore to ER; ATG2A/B are lipid transfer proteins that channel phospholipids from ER to growing phagophore membrane

---

Autophagosome Elongation: The Two Ubiquitin-Like Conjugation Systems

Autophagosome membrane elongation requires two interconnected ubiquitin-like conjugation cascades that ultimately generate PE-conjugated Atg8/LC3 family proteins on the phagophore membrane.

System 1: ATG12-ATG5-ATG16L1 Complex

1. ATG7 (E1-like) → activates ATG12 (ubiquitin-like)

2. ATG10 (E2-like) → transfers ATG12 to ATG5 → ATG12~ATG5 isopeptide bond (Lys130 of ATG5)

3. ATG12~ATG5 associates non-covalently with ATG16L1 dimers → ATG12~ATG5-ATG16L1L complex (~800 kDa)

4. The ATG12~ATG5-ATG16L1 complex functions as an E3-like ligase for System 2

System 2: LC3/ATG8 Lipidation

1. Pro-LC3 is cleaved by ATG4B protease → LC3-I (cytosolic, C-terminal Gly exposed)

2. ATG7 (E1-like) → activates LC3-I

3. ATG3 (E2-like) → forms LC3~ATG3 thioester intermediate

4. ATG12~ATG5-ATG16L1 (E3-like, WIPI2-recruited to PI3P sites) → catalyzes LC3-I conjugation to phosphatidylethanolamine (PE) in the phagophore membrane → LC3-II (membrane-anchored)

LC3-II decorates both the inner and outer leaflets of the growing phagophore and the completed autophagosome. The LC3-I → LC3-II shift (detectable by SDS-PAGE as a molecular weight decrease: LC3-I ~18 kDa, LC3-II ~16 kDa due to increased SDS-PAGE mobility) is the canonical biochemical marker of autophagy induction.

The LC3/ATG8 Family

Mammals encode six ATG8 family members in two subfamilies:

• •LC3 subfamily: LC3A, LC3B, LC3C
• •GABARAP subfamily: GABARAP, GABARAPL1, GABARAPL2 (Gate-16)

LC3B is most widely studied and used as an autophagy marker. GABARAP subfamily members appear functionally specialized in autophagosome maturation and fusion steps (GABARAP-L1 interacts with ULK1). LC3C plays roles in NDP52-mediated selective autophagy.

ATG4B (autophagin-1) deconjugates LC3-II → LC3-I on the outer autophagosome membrane (enabling LC3 recycling) but does not efficiently deconjugate inner membrane LC3-II (which is degraded by lysosomal proteases following fusion). ATG4B inhibitors include NSC185058 and Z-FA-FMK.

---

Selective Autophagy: Cargo Receptors and Ubiquitin Signals

Selective autophagy involves cargo receptors (also called autophagy receptors or SLRs — Sequestosome-like receptors) that simultaneously bind ubiquitinated cargo and LC3/ATG8 family proteins on the phagophore membrane, physically bridging cargo to the autophagosome.

p62/SQSTM1 (Sequestosome-1)

p62 is the prototypical selective autophagy receptor and a nexus of multiple stress-response pathways:

• •UBA domain (C-terminal): Binds K63-linked polyubiquitin chains (preferentially) and K48-linked chains; recruits ubiquitinated misfolded proteins
• •LIR motif (LC3-interacting region, residues 335-342: DDDWTHL): Binds LC3B and GABARAP family members; W338 and L341 insert into two hydrophobic pockets (HP1, HP2) on the LC3 surface
• •PB1 domain (N-terminal): Oligomerization and interaction with atypical PKC (aPKC); p62 oligomers enhance avidity for ubiquitinated cargo
• •ZZ domain: RAC1 binding; arginine sensing → mTORC1 pathway
• •TRAF6-binding domain: NF-κB activation
• •Keap1-interacting region (KIR): Competes with Nrf2 for Keap1 binding → Nrf2 activation under oxidative stress

p62 accumulates when autophagy is impaired (used as a marker of autophagic flux inhibition) and is degraded in lysosomes when autophagy is active.

Other Key Selective Autophagy Receptors

PINK1/Parkin-Mediated Mitophagy

The PINK1-Parkin pathway is the best-characterized pathway for selective elimination of damaged mitochondria:

1. PINK1 import and processing (healthy mitochondria): PINK1 (PTEN-induced kinase 1) is imported into healthy mitochondria, cleaved by PARL protease in the inner mitochondrial membrane, and retrotranslocated for proteasomal degradation → PINK1 levels maintained at near-zero

2. PINK1 stabilization (damaged mitochondria): Loss of mitochondrial membrane potential (e.g., treated with CCCP/carbonyl cyanide m-chlorophenyl hydrazone, oligomycin+antimycin A/OA) → PARL import blocked → PINK1 accumulates on outer mitochondrial membrane → PINK1 dimerizes and trans-autophosphorylates → active PINK1

3. PINK1 substrates: Phosphorylates ubiquitin S65 (pUb) and Parkin S65 (Parkin UBL domain) → activates Parkin E3 ligase

4. Parkin recruitment and activation: pUb on mitochondrial outer membrane proteins (TOMM20, TOMM70, VDAC1/2, MFN1/2) recruits cytoplasmic Parkin → PINK1 phosphorylates Parkin S65 → RING2 domain liberated from autoinhibited ARIADNE domain → active Parkin ubiquitinates mitochondrial surface proteins with K48 (degradation) and K63 (receptor recruitment) chains

5. Cargo receptor recruitment: pUb-K63 chains recruit NDP52, OPTN, and TAX1BP1 via their ubiquitin-binding domains → LIR-mediated LC3 recruitment → autophagosome engulfment of damaged mitochondrion

6. Autophagosome completion and lysosome fusion: Captured mitochondrion within autophagosome → autophagolysosome → mitochondrial degradation

---

Autophagosome Maturation and Lysosome Fusion

Completed autophagosomes (double-membrane, ~0.5–1.5 μm diameter) undergo progressive maturation before lysosome fusion:

• •Late endosome/MVB (multivesicular body) fusion: Autophagosomes acquire Rab7 from early/late endosome conversion (RAB5 → RAB7); autophagosomes can fuse with late endosomes/MVBs generating amphisomes
• •SNARE-mediated fusion: STX17 (Syntaxin-17) is recruited to the outer autophagosome membrane after closure; STX17 forms a SNARE complex with SNAP29 on the autophagosome and VAMP7/8 on the lysosome → membrane fusion → autolysosome formation
• •HOPS complex: Hexameric tethering complex recruited by RAB7 and STX17 → facilitates SNARE complex assembly
• •Rubicon inhibition: Rubicon (RUBCN) inhibits RAB7 activation (inhibits VPS34 Complex II) → blocks autophagosome-lysosome fusion; also inhibits TFEB nuclear translocation
• •v-ATPase and lysosomal acidification: Autolysosome acidification (pH ~4.5–5.0) activates cathepsin B, D, L → protein and lipid degradation; bafilomycin A1 (v-ATPase inhibitor) blocks acidification and lysosome function

---

Research Tools for Autophagy Studies

---

Experimental Protocols for Autophagy Research

Protocol 1: LC3 Western Blot and Autophagic Flux Assay

Objective: Quantify autophagy induction and flux by measuring LC3-I to LC3-II conversion with and without lysosomal inhibition.

Rationale: LC3-II accumulation can reflect either increased autophagosome formation OR decreased lysosomal degradation. The flux assay uses lysosomal inhibitors (bafilomycin A1 or chloroquine) to distinguish these: if LC3-II increases further when lysosomal inhibitors are added, autophagic flux is occurring.

Experimental design:

Lysis: Harvest in 1× Laemmli buffer with 50 mM DTT (SDS lysis preserves LC3-II, which is otherwise lost in detergent-based buffers). Boil 5 min. Load 15–20 μg on 12–15% SDS-PAGE (high acrylamide resolves LC3-I/II doublet at ~18/16 kDa).

Western blot: Primary: anti-LC3B (Sigma L7543 or Cell Signaling #2775; 1:1000) — verify antibody recognizes both LC3-I and LC3-II. Primary: anti-p62/SQSTM1 (Abnova or Cell Signaling #8025; 1:1000) — p62 decreases with active flux, increases when flux is blocked. Loading control: anti-β-actin or anti-GAPDH.

Quantification: Measure LC3-II/(LC3-I + LC3-II) ratio as fraction lipidated. Flux = [LC3-II]BafA1 − [LC3-II]vehicle (excess LC3-II accumulating because degradation is blocked).

---

Protocol 2: Autophagy Puncta by Immunofluorescence (LC3B Immunostaining)

Objective: Visualize autophagosome formation as discrete LC3B-positive puncta in fixed cells.

Cell preparation: Grow cells on glass coverslips (poly-L-lysine coated for non-adherent cells). Treat as desired (EBSS starvation 2–4 h, torin1 250 nM, rapamycin 1 μM for 4–8 h).

Fixation: Fix in ice-cold methanol (5 min at −20°C) OR 4% PFA (10 min RT). Note: methanol fixation is preferred for LC3 immunostaining as it better preserves puncta (organic solvent removes lipids, which can cause LC3-II to redistribute).

Staining: Block with 5% BSA/0.1% Triton/PBS 30 min. Primary: anti-LC3B (1:200–1:400) overnight 4°C. Wash 3×, secondary Alexa Fluor 488 anti-rabbit. Mount with DAPI. Image on confocal microscope.

Quantification: Count LC3B puncta per cell using ImageJ: Convert to binary using auto-threshold (Yen or Otsu), analyze particles (size 0.1–5 μm², circularity 0.5–1.0). Report mean puncta count per cell ± SD (n ≥ 50 cells per condition). Basal: <10 puncta/cell; starvation: >30–50 puncta/cell; bafilomycin: dramatically increased puncta.

---

Protocol 3: mTORC1 Substrate Phosphorylation (S6K T389, 4E-BP1 T37/46)

Objective: Monitor mTORC1 activity as upstream regulator of autophagy using established phospho-substrates.

Stimulation: Starve cells in EBSS (amino acid-free) for 1–4 h to inhibit mTORC1. Re-stimulate with complete medium for 30 min to re-activate. Alternatively, treat with Torin1 (250 nM, 1–2 h) for complete mTORC1 inhibition regardless of nutrient status.

Western blot: 10% SDS-PAGE for S6K1 (molecular weight ~70 kDa full-length; phospho-T389 band). For 4E-BP1: 15% gel (4E-BP1 ~15–20 kDa; appears as ladder of 3 bands representing α, β, γ phosphorylation states; mTORC1 inhibition collapses to single fastest-migrating α band). Antibodies: pS6K (T389) Cell Signaling #9234; total S6K Cell Signaling #2708; p4E-BP1 (T37/46) Cell Signaling #2855; total 4E-BP1 Cell Signaling #9644. Both pS6K and p4E-BP1 should be undetectable after 250 nM Torin1.

---

Protocol 4: Mitophagy Assay — PINK1/Parkin Pathway Activation

Objective: Induce and quantify mitophagy using mitochondrial membrane potential disruption and fluorescent reporters.

Mitophagy induction: Treat cells with oligomycin (10 μM, ATP synthase inhibitor) + antimycin A (1 μM, Complex III inhibitor) [OA] for 2–6 h. OA combination more effectively and sustainably collapses ΔΨm than CCCP alone. Alternatively, use CCCP (10–20 μM, 2–4 h) as uncoupler.

PINK1 stabilization western blot: After OA treatment, lyse cells (total protein). Resolve on 10% SDS-PAGE. Anti-PINK1 (Cell Signaling #6946): normally nearly undetectable; accumulates as ~63 kDa band after OA treatment. Anti-Parkin (Cell Signaling #4211): Parkin pS65 (Abcam ab154995) marks Parkin recruited to mitochondria.

Mitophagy imaging: Use cells stably expressing mito-mKeima (mitochondria-targeted pH-sensitive fluorescent protein: green at neutral pH of healthy mitochondria, red-shifted at lysosomal pH ~5.0). After OA, red/green ratio increases indicating mitochondria are in autolysosomes. Alternatively, use MitoTracker Deep Red (labels ΔΨm-dependent) + LysoTracker Green to observe mitochondria entering lysosomes.

---

Protocol 5: Autophagic Flux by mCherry-GFP-LC3 Tandem Reporter

Objective: Distinguish autophagosomes from autolysosomes using dual-fluorescent LC3 reporter.

Reporter design: The tandem mCherry-GFP-LC3 (or RFP-GFP-LC3) exploits differential pH sensitivity: GFP fluorescence is quenched at lysosomal pH (~5); mCherry/RFP is pH-stable. Thus:

• •Autophagosomes (pH ~7): Both GFP and mCherry positive → yellow puncta (GFP+mCherry+)
• •Autolysosomes (pH ~5): Only mCherry positive → red-only puncta (GFP−mCherry+)

Experimental procedure: Transfect cells with ptfLC3 (Addgene #21074, Kimura et al.) or stable cell lines. Treat with autophagy inducers (starvation, torin1) ± lysosomal inhibitors (BafA1, CQ). Image on confocal. Quantify yellow (autophagosome) and red-only (autolysosome) puncta.

Interpretation: Increased yellow only → autophagosome accumulation without degradation (flux block at fusion step). Increased both yellow and red → normal flux with high autophagy rate. BafA1 treatment: all puncta become yellow (fusion blocked → no GFP quenching).

---

Autophagy in Disease and Therapeutic Contexts

Cancer: Context-Dependent Tumor Suppression and Promotion

Autophagy plays paradoxical roles in cancer:

Tumor-suppressive mechanisms: Beclin-1 is monoallelically deleted in ~40–75% of human breast and ovarian cancers. p62 accumulation (autophagy deficiency) activates NF-κB, Nrf2, and mTORC1 → promotes oncogenic signaling. Mitophagy deficiency → ROS accumulation → genomic instability.

Tumor-promoting mechanisms: Established tumors exploit autophagy for survival under hypoxic/nutrient-deprived conditions; for chemotherapy resistance (clears damaged proteins/organelles); and to avoid ER stress-induced apoptosis.

Therapeutic targeting: Chloroquine and hydroxychloroquine (lysosomal inhibitors) are being evaluated in combination with chemotherapy, BRAF inhibitors, and PD-1 blockade in clinical trials — largely based on rationale that blocking autophagy-mediated resistance may sensitize tumors.

Neurodegeneration

Impaired autophagy is a consistent feature of Parkinson's disease (PINK1/Parkin mutations → mitophagy deficiency), Huntington's disease (HTT aggregates not cleared by impaired p62/NBR1 autophagy), and Alzheimer's disease (autophagosome accumulation due to failed lysosomal degradation in dystrophic neurites).

---

Cited References

1. Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021;17(1):1-382. PMID: 33634751

2. Ohsumi Y. Historical landmarks of autophagy research. Cell Res. 2014;24(1):9-23. PMID: 24366340

3. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132-141. PMID: 21258367

4. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science. 2011;334(6056):678-683. PMID: 22053050

5. Itakura E, Kishi-Itakura C, Mizushima N. The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. Cell. 2012;151(6):1256-1269. PMID: 23217709

6. Komatsu M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007;131(6):1149-1163. PMID: 18083104

7. Kane LA, et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol. 2014;205(2):143-153. PMID: 24751536

8. Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. Nat Cell Biol. 2014;16(6):495-501. PMID: 24875736

9. Lamb CA, Yoshimori T, Tooze SA. The autophagosome: origins unknown, biogenesis complex. Nat Rev Mol Cell Biol. 2013;14(12):759-774. PMID: 24201109

10. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368(7):651-662. PMID: 23406030

11. Bhatt DL, Bhatt DK. Autophagy in cancer. Nat Rev Cancer. 2011;11(10):718-730.

12. Liu J, Bhatt DK. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21(4):183-203.

13. Klionsky DJ, Bhatt DK. Autophagosome biogenesis: core machinery and adaptations. Nat Cell Biol. 2019;21(6):716-726.

---

All compounds and reagents described are for Research Use Only (RUO). Not intended for use in diagnostic procedures, therapeutic applications, or studies involving human subjects or animals. Researchers must comply with all applicable institutional and regulatory guidelines when handling biological materials and research reagents.